Last checked at 21 May 2019 07:00
HVIVO PLC
("hVIVO" or the "Company")
Exercise of Share Options
London, UK, 21 May 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 23,465 new ordinary shares of 5 pence each (the "New Ordinary Shares").
Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 24 May 2019.
Following Admission, the total number of ordinary shares with voting rights in issue will be 82,980,802 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information please contact:
hVIVO plc |
|
Trevor Phillips (Executive Chairman) | +44 207 756 1300 |
Fleur Wood (EVP, Investor Relations & Communications)
|
|
Numis Securities Limited | +44 207 260 1000 |
Freddie Barnfield (Nominated Adviser) |
|
James Black (Corporate Broking) |
|
|
|
FTI Consulting |
|
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.